By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company CSPC Pharmaceutical Group Limited

CSPC Pharmaceutical Group Limited (CHJTF)

OTC Market Data in USD, Fundamentals in HKD
$1.27
$0.00
0.00%
Last Update: 2 Sept 2025, 00:00
$14.57B
Market Cap
0.00
P/E Ratio (TTM)
2.82%
Forward Dividend Yield
$0.54 - $1.27
52 Week Range

CHJTF Stock Price Chart

Explore CSPC Pharmaceutical Group Limited interactive price chart. Choose custom timeframes to analyze CHJTF price movements and trends.

CHJTF Company Profile

Discover essential business fundamentals and corporate details for CSPC Pharmaceutical Group Limited (CHJTF) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Drug Manufacturers - General

IPO Date

5 Apr 2010

Employees

21.40K

CEO

Cuilong Zhang

Description

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

CHJTF Financial Timeline

Browse a chronological timeline of CSPC Pharmaceutical Group Limited corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 27 May 2026

Upcoming earnings on 26 Mar 2026

Upcoming earnings on 13 Nov 2025

Revenue estimate is $8.30B.

Earnings released on 22 Aug 2025

EPS came in at $0.03 , while revenue for the quarter reached $1.85B , missing expectations by -77.69%.

Dividend declared on 21 Aug 2025

A dividend of $0.02 per share was announced, adjusted to $0.02. The dividend will be paid on 18 Nov 2025.

Earnings released on 29 May 2025

EPS came in at $0.14 , while revenue for the quarter reached $7.52B , missing expectations by -6.95%.

Earnings released on 28 Mar 2025

Dividend declared on 28 Mar 2025

A dividend of $0.01 per share was announced, adjusted to $0.01. The dividend was paid on 18 Jul 2025.

Earnings released on 15 Nov 2024

Earnings released on 21 Aug 2024

EPS came in at $0.27 , while revenue for the quarter reached $17.50B .

Dividend declared on 21 Aug 2024

A dividend of $0.02 per share was announced, adjusted to $0.02. The dividend was paid on 20 Nov 2024.

Dividend declared on 31 May 2024

A dividend of $0.02 per share was announced, adjusted to $0.02. The dividend was paid on 26 Jun 2024.

Earnings released on 27 May 2024

Earnings released on 20 Mar 2024

EPS came in at $0.12 , while revenue for the quarter reached $34.60B .

Dividend declared on 20 Mar 2024

A dividend of $0.02 per share was announced, adjusted to $0.02. The dividend was paid on 26 Jun 2024.

Earnings released on 30 Dec 2023

EPS came in at $0.26 , while revenue for the quarter reached $16.60B .

Dividend declared on 23 Aug 2023

A dividend of $0.02 per share was announced, adjusted to $0.02. The dividend was paid on 12 Oct 2023.

Earnings released on 30 Jun 2023

EPS came in at $0.13 , while revenue for the quarter reached $8.03B .

Earnings released on 31 Mar 2023

EPS came in at $0.12 , while revenue for the quarter reached $8.05B .

Earnings released on 22 Mar 2023

EPS came in at $0.14 surpassing the estimated $0.12 by +16.67%, while revenue for the quarter reached $17.20B , beating expectations by +645.69%.

Dividend declared on 22 Mar 2023

A dividend of $0.01 per share was announced, adjusted to $0.01. The dividend was paid on 28 Jun 2023.

Earnings released on 22 Nov 2022

EPS came in at $0.13 surpassing the estimated $0.12 by +8.33%.

Earnings released on 24 Aug 2022

EPS came in at $0.13 falling short of the estimated $0.24 by -45.83%, while revenue for the quarter reached $18.85B , beating expectations by +708.10%.

Dividend declared on 24 Aug 2022

A dividend of $0.01 per share was announced, adjusted to $0.01. The dividend was paid on 11 Oct 2022.

Earnings released on 25 May 2022

EPS came in at $0.12 falling short of the estimated $0.16 by -25.00%.

Earnings released on 22 Mar 2022

EPS came in at $0.09 surpassing the estimated $0.08 by +12.50%, while revenue for the quarter reached $17.00B , beating expectations by +647.45%.

Dividend declared on 22 Mar 2022

A dividend of $0.01 per share was announced, adjusted to $0.01. The dividend was paid on 22 Jun 2022.

Earnings released on 17 Nov 2021

EPS came in at $0.11 matching the estimated $0.11.

Earnings released on 26 Aug 2021

EPS came in at $0.13 surpassing the estimated $0.11 by +18.18%, while revenue for the quarter reached $16.59B .

Dividend declared on 26 Aug 2021

A dividend of $0.01 per share was announced, adjusted to $0.01. The dividend was paid on 8 Oct 2021.

Earnings released on 24 May 2021

EPS came in at $0.12 surpassing the estimated $0.10 by +20.00%.

Earnings released on 15 Mar 2021

EPS came in at $0.14 surpassing the estimated $0.09 by +55.56%, while revenue for the quarter reached $14.13B , beating expectations by +535.95%.

Dividend declared on 15 Mar 2021

A dividend of $0.01 per share was announced, adjusted to $0.01. The dividend was paid on 11 Jun 2021.

Earnings released on 22 Nov 2020

EPS came in at $0.10 matching the estimated $0.10.

Stock split effective on 5 Nov 2020

Shares were split 8 : 5 , changing the number of shares outstanding and the price per share accordingly.

Dividend declared on 26 Aug 2020

A dividend of $0.01 per share was announced, adjusted to $0.01. The dividend was paid on 9 Oct 2020.

CHJTF Stock Performance

Access detailed CHJTF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run